Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

With the recent Health Canada approval of olaparib for high-risk, HER2-negative early breast cancer, physicians are now facing the practical challenges of integrating olaparib into current management of triple-negative breast cancer (TNBC) and HR-positive, HER2-negative (HR+/HER2−) early breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Henning, Jan-Willem, Boileau, Jean-François, Peck, Larissa, McFarlane, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453371/
https://www.ncbi.nlm.nih.gov/pubmed/37623037
http://dx.doi.org/10.3390/curroncol30080556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453371/
https://www.ncbi.nlm.nih.gov/pubmed/37623037
http://dx.doi.org/10.3390/curroncol30080556

Ejemplares similares